Back to top
more

Acasti Pharma (ACST)

(Delayed Data from NSDQ)

$2.93 USD

2.93
2,127

+0.03 (1.03%)

Updated Apr 25, 2024 11:41 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (159 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised

by Zacks Equity Research

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

by Zacks Equity Research

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

TEVA to Pay $250 Million to Settle Price-Fixing Charges

by Zacks Equity Research

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

by Zacks Equity Research

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

by Zacks Equity Research

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

TEVA Shares Rise on Broad Support for Opioids Settlement

by Zacks Equity Research

With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.

New Strong Sell Stocks for February 23rd

by Zacks Equity Research

ARR, ACST, and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on February 23, 2022

Acasti (ACST) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%

by Zacks Equity Research

Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

What Makes Acasti (ACST) a New Buy Stock

by Zacks Equity Research

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Indrajit Bandyopadhyay headshot

Uncertainty Looms Large Over Generic Drug Industry Players

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.

FDA Advisory Committee Recommends Mallinckrodt's Trelipressin

by Zacks Equity Research

The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.

FDA Advisory Committee to Review Mallinckrodt'sTerlipressin

by Zacks Equity Research

Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.

AstraZeneca to End Phase III Study on Fish Oil Heart Drug

by Zacks Equity Research

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

Amarin's Shares Down on Underperform Rating by Oppenheimer

by Zacks Equity Research

Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.

Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

by Zacks Equity Research

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

Indrajit Bandyopadhyay headshot

Price Stabilization Leads to Generic Drugs Industry's Recovery

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs is leading to a recovery in revenues of industry participants. New launches are also providing a boost. However, competition remains stiff.

Generic Industry on Path to Recovery: 3 Hot Picks for 2019

by Zacks Equity Research

The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.